The androgen receptor and VEGF: Mechanisms of androgen-regulated angiogenesis in prostate cancer

Cancers

Volumn 9, Issue 4, 2017, Pages

  Eisermann, Kurtis ^a   Fraizer, Gail ^a  

^a KENT STATE UNIVERSITY   (United States)

Author keywords

Androgen receptor; Angiogenesis; AR; CRPC; Hypoxia; Prostate cancer; VEGF

Indexed keywords

ANDROGEN RECEPTOR; BEVACIZUMAB; BICALUTAMIDE; DOCETAXEL; ENZALUTAMIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; MICRORNA; MICRORNA 125B2; MICRORNA 99A; MICRORNA LET7C; PREDNISONE; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; VASCULOTROPIN A; ZINC FINGER PROTEIN;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ANDROGEN DEPRIVATION THERAPY; ANGIOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; EPIGENETICS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSLATION REGULATION;

EID: 85018487408     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers9040032     Document Type: Review

References (69)

1. Heinlein, C.A.; Chang, C. Androgen receptor in prostate cancer. Endocr. Rev. 2004, 25, 276. [CrossRef] [PubMed]
2. Cleutjens, K.B.J.M.; van der Korput, H.A.G.M.; van Eekelen, C.C.E.M.; van Rooij, H.C.J.; Faber, P.W.; Trapman, J. An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol. Endocrinol. 1997, 11, 148. [CrossRef] [PubMed]
3. Tomlins, S.A.; Rhodes, D.R.; Perner, S.; Dhanasekaran, S.M.; Mehra, R.; Sun, X.W.; Varambally, S.; Cao, X.; Tchinda, J.; Kuefer, R.; et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310, 644–648. [CrossRef] [PubMed]
4. Lin, B.; Ferguson, C.; White, J.T.; Wang, S.; Vessella, R.; True, L.D.; Hood, L.; Nelson, P.S. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res. 1999, 59, 4180–4184. [PubMed]
5. He, W.W.; Sciavolino, P.J.; Wing, J.; Augustus, M.; Hudson, P.; Meissner, P.S.; Curtis, R.T.; Shell, B.K.; Bostwick, D.G.; Tindall, D.J. A novel human prostate-specific, androgen-regulated homeobox gene (NKX3. 1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics 1997, 43, 69–77. [CrossRef] [PubMed]
6. Magee, J.A.; Chang, L.; Stormo, G.D.; Milbrandt, J. Direct, androgen receptor-mediated regulation of the FKBP5 gene via a distal enhancer element. Endocrinology 2006, 147, 590–598. [CrossRef] [PubMed]
7. O’Malley, B.W.; Kumar, R. Nuclear receptor coregulators in cancer biology. Cancer Res. 2009, 69, 8217–8222. [CrossRef] [PubMed]
8. Heemers, H.V.; Tindall, D.J. Androgen receptor (AR) coregulators: A diversity of functions converging on and regulating the AR transcriptional complex. Endocr. Rev. 2007, 28, 778–808. [CrossRef] [PubMed]
9. Agoulnik, I.U.; Weigel, N.L. Androgen Receptor Coactivators and Prostate Cancer. In Hormonal Carcinogenesis V; Springer: New York, NY, USA, 2008.
10. Wang, L.; Hsu, C.; Chang, C. Androgen receptor corepressors: An overview. Prostate 2005, 63, 117–130. [CrossRef] [PubMed]
11. Moyer, V.A. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann. Intern. Med. 2012, 157, 120–134. [CrossRef] [PubMed]
12. Fox, W.D.; Higgins, B.; Maiese, K.M.; Drobnjak, M.; Cordon-Cardo, C.; Scher, H.I.; Agus, D.B. Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clin. Cancer Res. 2002, 8, 3226–3231. [PubMed]
13. Delongchamps, N.B.; Peyromaure, M.; Dinh-Xuan, A.T. Role of vascular endothelial growth factor in prostate cancer. Urology 2006, 68, 244–248. [CrossRef] [PubMed]
14. Forsythe, J.A.; Jiang, B.H.; Iyer, N.V.; Agani, F.; Leung, S.W.; Koos, R.D.; Semenza, G.L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell Biol. 1996, 16, 4604–4613. [CrossRef] [PubMed]
15. Stewart, R.J.; Panigrahy, D.; Flynn, E.; Folkman, J. Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J. Urol. 2001, 165, 688–693. [CrossRef] [PubMed]
16. Eisermann, K.; Broderick, C.J.; Bazarov, A.; Moazam, M.M.; Fraizer, G.C. Androgen up-regulates vascular endothelial growth factor expression in prostate cancer cells via an Sp1 binding site. Mol. Cancer 2013, 12, 7. [CrossRef] [PubMed]
17. Joseph, I.B.; Nelson, J.B.; Denmeade, S.R.; Isaacs, J.T. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin. Cancer Res. 1997, 3, 2507–2511. [PubMed]
18. Fraizer, G.C.; Eisermann, K.; Pandey, S.; Brett-Morris, A.; Bazarov, A.; Nock, S.; Ghimirey, N.; Kuerbitz, S.J. Functional Role of WT1 in Prostate Cancer. In Wilms Tumor; Codon Publications: Brisbane, Australia, 2016.
19. McKay, R.R.; Zurita, A.J.; Werner, L.; Bruce, J.Y.; Carducci, M.A.; Stein, M.N.; Heath, E.I.; Hussain, A.; Tran, H.T.; Sweeney, C.J.; et al. A randomized phase II trial of short-course androgen deprivation therapy with or without bevacizumab for patients with recurrent prostate cancer after Definitive local therapy. J. Clin. Oncol. 2016, 34, 1913–1920. [CrossRef] [PubMed]
20. Fernandez, E.V.; Reece, K.M.; Ley, A.M.; Troutman, S.M.; Sissung, T.M.; Price, D.K.; Chau, C.H.; Figg, W.D. Dual targeting of the androgen receptor and hypoxia-inducible factor 1alpha pathways synergistically inhibits castration-resistant prostate cancer cells. Mol. Pharmacol. 2015, 87, 1006–1012. [CrossRef] [PubMed]
21. Loureiro, R.M.; D’Amore, P.A. Transcriptional regulation of vascular endothelial growth factor in cancer. Cytokine Growth Factor Rev. 2005, 16, 77–89. [CrossRef] [PubMed]
22. de Brot, S.; Ntekim, A.; Cardenas, R.; James, V.; Allegrucci, C.; Heery, D.M.; Bates, D.O.; Odum, N.; Persson, J.L.; Mongan, N.P. Regulation of vascular endothelial growth factor in prostate cancer. Endocr. Relat. Cancer 2015, 22, R107–123. [CrossRef] [PubMed]
23. Wagner, K.D.; Wagner, N.; Vidal, V.P.I.; Schley, G.; Wilhelm, D.; Schedl, A.; Englert, C.; Scholz, H. The Wilms’ tumor gene Wt1 is required for normal development of the retina. EMBO J. 2002, 21, 1398–1405. [CrossRef] [PubMed]
24. Hanson, J.; Gorman, J.; Reese, J.; Fraizer, G. Regulation of vascular endothelial growth factor, VEGF, gene promoter by the tumor suppressor, WT1. Front Biosci. 2007, 12, 2279–2290. [CrossRef] [PubMed]
25. Sordello, S.; Bertrand, N.; Plouet, J. Vascular endothelial growth factor is up-regulated in vitro and in vivo by androgens. Biochem. Biophys. Res. Commun. 1998, 251, 287–290. [CrossRef] [PubMed]
26. Aslan, G.; Cimen, S.; Yorukoglu, K.; Tuna, B.; Sonmez, D.; Mungan, U.; Celebi, I. Vascular endothelial growth factor expression in untreated and androgen-deprived patients with prostate cancer. Pathol. Res. Pract. 2005, 201, 593–598. [CrossRef] [PubMed]
27. Smith, L.B.; Walker, W.H. The regulation of spermatogenesis by androgens. Semin. Cell Dev. Biol. 2014, 30, 2–13. [CrossRef] [PubMed]
28. Metzger, E.; Wissmann, M.; Yin, N.; Müller, J.M.; Schneider, R.; Peters, A.H.; Günther, T.; Buettner, R.; Schüle, R. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 2005, 437, 436–439. [CrossRef] [PubMed]
29. Kashyap, V.; Ahmad, S.; Nilsson, E.M.; Helczynski, L.; Kenna, S.; Persson, J.L.; Gudas, L.J.; Mongan, N.P. The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer. Mol. Oncol. 2013, 7, 555–566. [CrossRef] [PubMed]
30. Cai, C.; He, H.H.; Chen, S.; Coleman, I.; Wang, H.; Fang, Z.; Chen, S.; Nelson, P.S.; Liu, X.S.; Brown, M. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell 2011, 20, 457–471. [CrossRef] [PubMed]
31. Deng, X.; Shao, G.; Zhang, H.; Li, C.; Zhang, D.; Cheng, L.; Elzey, B.; Pili, R.; Ratliff, T.; Huang, J. Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth. Oncogene 2016, 36, 1223–1231. [CrossRef] [PubMed]
32. Levy, A.P.; Levy, N.S.; Goldberg, M.A. Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J. Biol. Chem. 1996, 271, 2746–2753. [CrossRef] [PubMed]
33. Levy, N.S.; Chung, S.; Furneaux, H.; Levy, A.P. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J. Biol. Chem. 1998, 273, 6417–6423. [CrossRef] [PubMed]
34. Shih, S.C.; Claffey, K.P. Regulation of human vascular endothelial growth factor mRNA stability in hypoxia by heterogeneous nuclear ribonucleoprotein L. J. Biol. Chem. 1999, 274, 1359–1365. [CrossRef] [PubMed]
35. Chang, S.H.; Lu, Y.C.; Li, X.; Hsieh, W.Y.; Xiong, Y.; Ghosh, M.; Evans, T.; Elemento, O.; Hla, T. Antagonistic function of the RNA-binding protein HuR and miR-200b in post-transcriptional regulation of vascular endothelial growth factor-A expression and angiogenesis. J. Biol. Chem. 2013, 288, 4908–4921. [CrossRef] [PubMed]
36. Ray, P.S.; Jia, J.; Yao, P.; Majumder, M.; Hatzoglou, M.; Fox, P.L. A stress-responsive RNA switch regulates VEGFA expression. Nature 2009, 457, 915–919. [CrossRef] [PubMed]
37. Jafarifar, F.; Yao, P.; Eswarappa, S.M.; Fox, P.L. Repression of VEGFA by CA-rich element-binding microRNAs is modulated by hnRNP L. EMBO J. 2011, 30, 1324–1334. [CrossRef] [PubMed]
38. Arcondeguy, T.; Lacazette, E.; Millevoi, S.; Prats, H.; Touriol, C. VEGF-A mRNA processing, stability and translation: A paradigm for intricate regulation of gene expression at the post-transcriptional level. Nucleic Acids Res. 2013, 41, 7997–8010. [CrossRef] [PubMed]
39. Sun, D.; Layer, R.; Mueller, A.C.; Cichewicz, M.A.; Negishi, M.; Paschal, B.M.; Dutta, A. Regulation of several androgen-induced genes through the repression of the miR-99a/let-7c/miR-125b-2 miRNA cluster in prostate cancer cells. Oncogene 2014, 33, 1448–1457. [CrossRef] [PubMed]
40. Morris, M.J.; Negishi, Y.; Pazsint, C.; Schonhoft, J.D.; Basu, S. An RNA G-quadruplex is essential for cap-independent translation initiation in human VEGF IRES. J. Am. Chem. Soc. 2010, 132, 17831–17839. [CrossRef] [PubMed]
41. Bornes, S.; Prado-Lourenco, L.; Bastide, A.; Zanibellato, C.; Iacovoni, J.S.; Lacazette, E.; Prats, A.C.; Touriol, C.; Prats, H. Translational induction of VEGF internal ribosome entry site elements during the early response to ischemic stress. Circ. Res. 2007, 100, 305–308. [CrossRef] [PubMed]
42. Sfar, S.; Hassen, E.; Saad, H.; Mosbah, F.; Chouchane, L. Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome. Cytokine 2006, 35, 21–28. [CrossRef] [PubMed]
43. Bornes, S.; Boulard, M.; Hieblot, C.; Zanibellato, C.; Iacovoni, J.S.; Prats, H.; Touriol, C. Control of the Vascular Endothelial Growth Factor Internal Ribosome Entry Site (IRES) Activity and Translation Initiation by Alternatively Spliced Coding Sequences. J. Biol. Chem. 2004, 279, 18717–18726. [CrossRef] [PubMed]
44. Levine, A.C.; Liu, X.H.; Greenberg, P.D.; Eliashvili, M.; Schiff, J.D.; Aaronson, S.A.; Holland, J.F.; Kirschenbaum, A. Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts. Endocrinology 1998, 139, 4672–4678. [CrossRef] [PubMed]
45. Li, J.; Wang, E.; Rinaldo, F.; Datta, K. Upregulation of VEGF-C by androgen depletion: the involvement of IGF-IR-FOXO pathway. Oncogene 2005, 24, 5510–5520. [CrossRef] [PubMed]
46. ′ -kinase/protein kinase B in prostate cancer cells. Clin. Cancer Res. 2003, 9, 2416. [PubMed]
47. Wang, Q.; Li, W.; Liu, X.S.; Carroll, J.S.; Jänne, O.A.; Keeton, E.K.; Chinnaiyan, A.M.; Pienta, K.J.; Brown, M. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol. Cell 2007, 27, 380–392. [CrossRef] [PubMed]
48. Bolton, E.C.; So, A.Y.; Chaivorapol, C.; Haqq, C.M.; Li, H.; Yamamoto, K.R. Cell- and gene-specific regulation of primary target genes by the androgen receptor. Genes Dev. 2007, 21, 2005–2017. [CrossRef] [PubMed]
49. Massie, C.E.; Adryan, B.; Barbosa-Morais, N.L.; Lynch, A.G.; Tran, M.G.; Neal, D.E.; Mills, I.G. New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep. 2007, 8, 871. [CrossRef] [PubMed]
50. Eisermann, K.; Bazarov, A.; Brett, A.; Knapp, E.; Piontkivska, H.; Fraizer, G. Uncovering androgen responsive regulatory networks in prostate cancer. In Proceedings of the Ohio Collaborative Conference on Bioinformatics, Cleveland, OH, USA, 15–17 June 2009.
51. Mueller, M.D.; Vigne, J.L.; Minchenko, A.; Lebovic, D.I.; Leitman, D.C.; Taylor, R.N. Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors alpha and beta. Proc. Natl. Acad. Sci. USA 2000, 97, 10972–10977. [CrossRef] [PubMed]
52. Stoner, M.; Wormke, M.; Saville, B.; Samudio, I.; Qin, C.; Abdelrahim, M.; Safe, S. Estrogen regulation of vascular endothelial growth factor gene expression in ZR-75 breast cancer cells through interaction of estrogen receptor a and SP proteins. Oncogene 2004, 23, 1052–1063. [CrossRef] [PubMed]
53. Kimbro, K.S.; Simons, J.W. Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr. Relat. Cancer 2006, 13, 739–749. [CrossRef] [PubMed]
54. Zhong, H.; Semenza, G.L.; Simons, J.W.; De Marzo, A.M. Up-regulation of hypoxia-inducible factor 1α is an early event in prostate carcinogenesis. Cancer Detect. Prev. 2004, 28, 88–93. [CrossRef] [PubMed]
55. Ragnum, H.B.; Røe, K.; Holm, R.; Vlatkovic, L.; Nesland, J.M.; Aarnes, E.; Ree, A.H.; Flatmark, K.; Seierstad, T.; Lilleby, W. Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2013, 87, 753–760. [CrossRef] [PubMed]
56. Horii, K.; Suzuki, Y.; Kondo, Y.; Akimoto, M.; Nishimura, T.; Yamabe, Y.; Sakaue, M.; Sano, T.; Kitagawa, T.; Himeno, S.; et al. Androgen-dependent gene expression of prostate-specific antigen is enhanced synergistically by hypoxia in human prostate cancer cells. Mol. Cancer Res. 2007, 5, 383–391. [CrossRef] [PubMed]
57. Mitani, T.; Harada, N.; Nakano, Y.; Inui, H.; Yamaji, R. Coordinated action of hypoxia-inducible factor-1alpha and beta-catenin in androgen receptor signaling. J. Biol. Chem. 2012, 287, 33594–33606. [CrossRef] [PubMed]
58. Antonarakis, E.; Armstrong, A.; Dehm, S.; Luo, J. Androgen receptor variant-driven prostate cancer: Clinical implications and therapeutic targeting. Prostate Cancer Prostatic Dis. 2016, 19, 231–241. [CrossRef] [PubMed]
59. Hörnberg, E.; Ylitalo, E.B.; Crnalic, S.; Antti, H.; Stattin, P.; Widmark, A.; Bergh, A.; Wikström, P. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS ONE 2011, 6, e19059. [CrossRef] [PubMed]
60. Sun, S.; Sprenger, C.C.; Vessella, R.L.; Haugk, K.; Soriano, K.; Mostaghel, E.A.; Page, S.T.; Coleman, I.M.; Nguyen, H.M.; Sun, H.; et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J. Clin. Investig. 2010, 120, 2715–2730. [CrossRef] [PubMed]
61. Hu, R.; Dunn, T.A.; Wei, S.; Isharwal, S.; Veltri, R.W.; Humphreys, E.; Han, M.; Partin, A.W.; Vessella, R.L.; Isaacs, W.B.; et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009, 69, 16–22. [CrossRef] [PubMed]
62. Efstathiou, E.; Titus, M.; Wen, S.; Hoang, A.; Karlou, M.; Ashe, R.; Tu, S.M.; Aparicio, A.; Troncoso, P.; Mohler, J. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur. Urol. 2015, 67, 53–60. [CrossRef] [PubMed]
63. Antonarakis, E.S.; Lu, C.; Wang, H.; Luber, B.; Nakazawa, M.; Roeser, J.C.; Chen, Y.; Mohammad, T.A.; Chen, Y.; Fedor, H.L. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 2014, 371, 1028–1038. [CrossRef] [PubMed]
64. Dehm, S.M.; Schmidt, L.J.; Heemers, H.V.; Vessella, R.L.; Tindall, D.J. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 2008, 68, 5469–5477. [CrossRef] [PubMed]
65. Wadosky, K.M.; Koochekpour, S. Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer. Oncotarget 2016, 7, 64447–64470. [CrossRef] [PubMed]
66. Ferrer, F.A.; Miller, L.J.; Andrawis, R.I.; Kurtzman, S.H.; Albertsen, P.C.; Laudone, V.P.; Kreutzer, D.L. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: In situ and in vitro expression of VEGF by human prostate cancer cells. J. Urol. 1997, 157, 2329–2333. [CrossRef]
67. Duque, J.L.F.; Loughlin, K.R.; Adam, R.M.; Kantoff, P.W.; Zurakowski, D.; Freeman, M.R. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 1999, 54, 523–527. [CrossRef]
68. Duque, J.L.F.; Loughlin, K.R.; Adam, R.M.; Kantoff, P.; Mazzucchi, E.; Freeman, M.R. Measurement of plasma levels of vascular endothelial growth factor in prostate cancer patients: Relationship with clinical stage, Gleason score, prostate volume, and serum prostate-specific antigen. Clinics 2006, 61, 401–408. [CrossRef] [PubMed]
69. Kelly, W.K.; Halabi, S.; Carducci, M.; George, D.; Mahoney, J.F.; Stadler, W.M.; Morris, M.; Kantoff, P.; Monk, J.P.; Kaplan, E. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J. Clin. Oncol. 2012, 30, 1534–1540. [CrossRef] [PubMed]